Although it is known that up to 80% of nevi harbor BRAFV600E mutations, it has not been clear whether mutations occur in the development of the nevus or whether the BRAF change develops later, after other nevus-initiating events have already been triggered. One way to address this controversy is to analyze the cell-by-cell genetic profile within nevus lesions. If mutation occurred early on, then most, if not all, of the cells should harbor the BRAF mutation. If mutation was a late event, then only some cells should contain the mutation.
These authors used droplet digital polymerase chain reaction to assess the frequency of cells with BRAFV600E mutations within acquired nevi. In BRAF-mutant nevi, the number of BRAF-mutant alleles equaled the …
Reviewing Author
DisclosuresConsultant / advisory board Lubax; WorldCare Clinical
EquityLubax
Grant / Research support NIH; Department of Defense; American Skin Association; Piramal
Editorial boardsBritish Journal of Dermatology; Journal of the American Academy of Dermatology; Journal of Investigative Dermatology
Leadership positions in professional societies American Academy of Dermatology (Chair, Skin Cancer and Melanoma Committee); American Board of Dermatology (Director)
DisclosuresConsultant / advisory board Lubax; WorldCare Clinical
EquityLubax
Grant / Research support NIH; Department of Defense; American Skin Association; Piramal
Editorial boardsBritish Journal of Dermatology; Journal of the American Academy of Dermatology; Journal of Investigative Dermatology
Leadership positions in professional societies American Academy of Dermatology (Chair, Skin Cancer and Melanoma Committee); American Board of Dermatology (Director)